Researchers reported a manufacturing-forward approach to improve upstream stability in large-scale AAV production by reducing the volume and time sensitivity of transfection complex additions. The approach centers on VirusGEN Transfection Complex Stabilizer, intended to extend complex stability while supporting higher process robustness. The workflow targets an operational bottleneck for scaling, where transfection complex addition must occur within a narrow window to preserve yield. By cutting the required complex volume from roughly 5% to 2% of total cell culture volume and stabilizing it for up to three hours, the method aims to reduce dilution effects, labor, and downstream purification pressure. Experimental results described in the report indicate that AAV titer and full-capsid percentages can improve when used as part of a fully optimized VirusGEN workflow. While described as additive-support for established components (e.g., Trans IT transfection reagent and Rev IT enhancer), the practical value for developers is straightforward: fewer time-critical steps as patient populations expand and manufacturing capacity needs increase.